Phenprocoumon
Appearance
Clinical data | |
---|---|
Trade names | Marcoumar, Marcumar, Falithrom |
AHFS/Drugs.com | International Drug Names |
MedlinePlus | a699003 |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | 99% |
Metabolism | hepatic to inactive metabolites |
Elimination half-life | 5 to 6 days |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.006.464 |
Chemical and physical data | |
Formula | C18H16O3 |
Molar mass | 280.318 g/mol g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Phenprocoumon (marketed under the brand names Marcoumar, Marcumar and Falithrom) is a long-acting oral anticoagulant drug, a derivative of coumarin. It is a vitamin K antagonist that inhibits coagulation by blocking synthesis of coagulation factors II, VII, IX and X. It is used for the prophylaxis and treatment of thromboembolic disorders (thrombosis/pulmonary embolism). It is the standard coumarin used in Germany.
Phenprocoumon is a 4-hydroxycoumarin and inhibits vitamin K epoxide reductase.[1]
References
- ^ Phenprocoumon at PharmGKB
External links
- Diseases Database (DDB): 29943